FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Meyer Robert J.
2. Issuer Name and Ticker or Trading Symbol

CHIMERIX INC [ CMRX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100
3. Date of Earliest Transaction (MM/DD/YYYY)

11/6/2019
(Street)

DURHAM, NC 27713
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  11/6/2019    P    10000  A $1.5797 (1) 10000  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Meyer Robert J.
C/O CHIMERIX, INC.
2505 MERIDIAN PARKWAY, SUITE 100
DURHAM, NC 27713
X



Signatures
/s/ Michael Alrutz, Attorney-In-Fact 11/6/2019
**Signature of Reporting Person Date


Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Chimerix Charts.
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Chimerix Charts.

Chimerix Inc News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
Wednesday 1 May 2024 (4 days ago) • GlobeNewswire Inc.
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
Wednesday 24 April 2024 (2 weeks ago) • GlobeNewswire Inc.
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 17 April 2024 (3 weeks ago) • GlobeNewswire Inc.
Chimerix Appoints Marc D. Kozin to Board of Directors
Thursday 21 March 2024 (1 month ago) • GlobeNewswire Inc.
Form S-3 - Registration statement under Securities Act of 1933
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
Thursday 22 February 2024 (2 months ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (3 months ago) • Edgar (US Regulatory)